CY1111213T1 - Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας - Google Patents

Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας

Info

Publication number
CY1111213T1
CY1111213T1 CY20111100212T CY111100212T CY1111213T1 CY 1111213 T1 CY1111213 T1 CY 1111213T1 CY 20111100212 T CY20111100212 T CY 20111100212T CY 111100212 T CY111100212 T CY 111100212T CY 1111213 T1 CY1111213 T1 CY 1111213T1
Authority
CY
Cyprus
Prior art keywords
igf
binding protein
patient
risk
preterm birth
Prior art date
Application number
CY20111100212T
Other languages
English (en)
Inventor
Lois Smith
Ann Hellström
Original Assignee
Premacure Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004405A external-priority patent/SE0004405D0/xx
Application filed by Premacure Ab filed Critical Premacure Ab
Publication of CY1111213T1 publication Critical patent/CY1111213T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)

Abstract

Σε μία πλευρά της παρούσας εφεύρεσης παρέχεται μέθοδος για προσδιορισμό κινδύνου ανάπτυξης επιπλοκής πρόωρης γέννησης σε ασθενή γεννηθέντα πριν την 40η εβδομάδα κύησης ή που ζυγίζει 10% λιγότερο από το μέσο για την ηλικία κύησης του ασθενούς. Η μέθοδος περιλαμβάνει μέτρηση των επιπέδων IGF-I και/ή πρωτεΐνης IGF-I-δέσμευσης στον ορό μετά τη γέννηση του ασθενούς για τη λήψη επιπέδου του IGF-I ή της πρωτεΐνης IGF-I-δέσμευσης˙ και συσχέτιση του εν λόγω επιπέδου του IGF-I ή πρωτεΐνης IGF-I-δέσμευσης με επίπεδο γραμμής βάσης, εντός μήτρας, της πρωτεΐνης IGF-I-δέσμευσης με βάση μέσα επίπεδα, εντός μήτρας, εξομοιωμένα ως προς την ηλικία κύησης, όπου επίπεδο του IGF-I ή της πρωτεΐνης IGF-I-δέσμευσης κάτω από το μέσο επίπεδο, εντός μήτρας, ηλικίας κύησης δηλώνει ότι ο ασθενής είναι σε αυξημένο κίνδυνο ανάπτυξης επιπλοκής πρόωρης γέννησης. Οι επιπλοκές της πρόωρης γέννησης περιλαμβάνουν αμφιβλητροειδοπάθεια πρωιμότητας, καθυστέρηση ανάπτυξης, διανοητική καθυστέρηση, βρογχοπνευμονική δυσπλασία, και ενδοκοιλιακή αιμορραγία. Επίσης παρέχονται μέθοδοι για την αγωγή/πρόληψη επιπλοκών πρόωρης γέννησης.
CY20111100212T 2000-11-28 2011-02-22 Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας CY1111213T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004405A SE0004405D0 (sv) 2000-11-28 2000-11-28 New composition and use
US27425201P 2001-03-09 2001-03-09
EP01987331A EP1402266B1 (en) 2000-11-28 2001-11-13 Reducing RISK OF COMPLICATIONS OF PREMATURITY

Publications (1)

Publication Number Publication Date
CY1111213T1 true CY1111213T1 (el) 2015-06-11

Family

ID=26655321

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100212T CY1111213T1 (el) 2000-11-28 2011-02-22 Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας

Country Status (9)

Country Link
US (2) US7144707B2 (el)
EP (1) EP1402266B1 (el)
JP (2) JP4173732B2 (el)
AT (1) ATE495443T1 (el)
AU (2) AU2002239560B2 (el)
CA (1) CA2429615C (el)
CY (1) CY1111213T1 (el)
DE (1) DE60143858D1 (el)
WO (1) WO2002043578A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418937A4 (en) * 2001-07-27 2005-08-03 Hartmut M Hanauske-Abel IMPROVEMENT OF ORGANIZATION IN NEWBORN AND PREDICTION OF THE DURATION OF INTENSIVE MEDICAL CARE
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
JP5449134B2 (ja) * 2007-04-18 2014-03-19 プレーマクレ・アクチエボラーグ 未熟児合併症の治療及び／又は予防の方法と製品
US7871785B2 (en) 2007-09-07 2011-01-18 Children's Hospital Medical Center Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
CA2704746A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
JP5398054B2 (ja) * 2008-08-20 2014-01-29 株式会社 資生堂 「シミ」の蓋然性の評価方法
DK2451462T3 (en) 2009-07-06 2017-12-11 Children's Hospital Medical Center Inhibition of inflammation with milk oligosaccharides
RU2445945C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445946C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445943C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445944C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
RU2526827C1 (ru) * 2013-05-23 2014-08-27 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ прогнозирования развития пороговой стадии ретинопатии недоношенных у детей без офтальмологических признаков заболевания
JP5559406B2 (ja) * 2013-09-11 2014-07-23 株式会社 資生堂 シミを有する蓋然性を評価する方法
RU2536284C1 (ru) * 2013-09-19 2014-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Министерства здравоохранения Российской Федерации" (ГБОУ ВПО РНИМУ Минздрава России) Способ оценки тяжести течения и возможного исхода ретинопатии у недоношенных детей
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
RU2639134C2 (ru) * 2016-01-21 2017-12-19 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у новорожденных, родившихся после экстракорпорального оплодотворения
EP3681602A1 (en) * 2017-09-11 2020-07-22 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases
RU2741722C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования внутрижелудочковых кровоизлияний у недоношенных новорожденных
RU2741727C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у недоношенных новорожденных
EP3936054A1 (en) * 2020-07-08 2022-01-12 Assistance Publique - Hôpitaux de Paris Method of prognosis of bronchopulmonary dysplasia in premature infants
CN113528688A (zh) * 2021-09-09 2021-10-22 北京泱深生物信息技术有限公司 微生物在制备用于诊断生长发育迟缓的产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015142A1 (en) * 1989-06-09 1990-12-13 Gropep Pty. Ltd. Growth hormone fusion proteins
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP1418937A4 (en) 2001-07-27 2005-08-03 Hartmut M Hanauske-Abel IMPROVEMENT OF ORGANIZATION IN NEWBORN AND PREDICTION OF THE DURATION OF INTENSIVE MEDICAL CARE

Also Published As

Publication number Publication date
WO2002043578A2 (en) 2002-06-06
ATE495443T1 (de) 2011-01-15
EP1402266B1 (en) 2011-01-12
DE60143858D1 (de) 2011-02-24
US7144707B2 (en) 2006-12-05
JP4173732B2 (ja) 2008-10-29
WO2002043578A3 (en) 2003-12-31
AU3956002A (en) 2002-06-11
EP1402266A4 (en) 2007-12-12
JP2008163043A (ja) 2008-07-17
CA2429615C (en) 2016-07-12
US20040053838A1 (en) 2004-03-18
US20070196857A1 (en) 2007-08-23
EP1402266A2 (en) 2004-03-31
JP5089443B2 (ja) 2012-12-05
US7776820B2 (en) 2010-08-17
JP2004528529A (ja) 2004-09-16
AU2002239560B2 (en) 2006-03-02
CA2429615A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CY1111213T1 (el) Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας
Asamiya et al. The importance of low blood urea nitrogen levels in pregnant patients undergoing hemodialysis to optimize birth weight and gestational age
Bacq et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls
Geethanath et al. Effect of timing of cord clamping on the iron status of infants at 3 months
Austin et al. Pregnancy-specific protein B induces release of an alpha chemokine in bovine endometrium
Andersen et al. Management of thyrotoxicosis during pregnancy
Erdem et al. The effect of maternal anemia and iron deficiency on fetal erythropoiesis: comparison between serum erythropoietin, hemoglobin and ferritin levels in mothers and newborns
Okuyama et al. The role of transferrin and ferritin in the fetal-maternalplacental unit
Giacobbe et al. Thyroid diseases in pregnancy: a current and controversial topic on diagnosis and treatment over the past 20 years
Halliday Elective delivery at “term”: implications for the newborn
Zimanyi et al. Nephron number and blood pressure in rat offspring with maternal high-protein diet
Mühle et al. No juvenile arterial hypertension in sheep multiples despite reduced nephron numbers
Rehema et al. Ferrous iron administration during pregnancy and adaptational oxidative stress (Pilot study)
Setia et al. Increased insulin sensitivity in intrauterine growth retarded newborns–Do thyroid hormones play a role?
Taghavi et al. Outcome of thyroid dysfunction in pregnancy in Mashhad, Iran
Xu et al. Maternal menstrual history and small-for-gestational-age births in a population-based Chinese birth cohort
Brandenberger et al. CA-125 concentrations in the serum and pregnancy outcome in IVF cycles
Farman et al. Present Perspectives of Hyperthyroidism during Pregnancy
McGrath et al. Corticotrophin-releasing hormone and parturition.
Wagh et al. Thyroid screening in pregnancy
Pluta et al. Macro-TSH—tips and tricks for gynecologists
Hsu et al. Maternal serum screening for Down syndrome in pregnancies conceived by intra‐uterine insemination
Weems et al. Effects of prostaglandin F2α (PGF2α) on secretion of pregnancy specific protein B (PSPB) and placentome weights in intact or ovariectomized 90 to 100 day pregnant ewes
Satyanarayan et al. Maternal thyroid profile in pre-eclampsia
Kausar Hyperthyroidism and Its Implications for Diagnosis and Management of Complications During Pregnancy